Zum Inhalt springen
Aperlena

Ireland - Laboratory reagents - Provision of Flow Cytometry Reagents, Antibodies, Platform-Specific Consumables and Single-Cell Genomics Reagents for Ongoing Research Activities

Vergeben Vergabebekanntmachung Keine Frist veröffentlicht
Ausschreibung beobachten

Die Angebotsfrist ist vorbei. Ein Zuschlag oder eine Berichtigung zu dieser Bekanntmachung: eine E-Mail, wenn das Register es sieht. Anmelden

  1. Vergeben
  2. Veröffentlicht

Beschreibung

This voluntary ex-ante transparency (VEAT) notice acknowledges that Trinity College Dublin proposes to put in place a contract with Becton Dickinson UK Ltd, 1030 Eskdale Road, Winnersh Triangle, Wokingham, Berkshire RG41 5TS for the provision of flow cytometry reagents, antibodies, platform-specific consumables and single-cell genomics reagents required to support ongoing research activities across the University. The requirement encompasses specialised laboratory reagents, including fluorochrome-conjugated monoclonal antibodies, staining buffers, assay kits, instrument calibration materials, and proprietary consumables associated with BD flow cytometry and BD Rhapsody single-cell genomics platforms. These products are integral to established experimental workflows across multiple research groups, including immunophenotyping, cell signalling analysis and single-cell gene expression studies. Trinity College Dublin intends to award this contract in accordance with Article 32(2)(b)(ii) of Directive 2014/24/EU, on the basis that competition is absent for technical reasons. The required reagents are defined by specific antibody clones and fluorochrome conjugations, many of which are proprietary and are embedded within validated experimental protocols. Substitution would necessitate extensive re-validation, introduce scientific risk and delay research outputs. In addition, platform-specific consumables, including BD Rhapsody cartridge and cDNA kits are required for the operation of existing instrumentation and cannot be replaced with alternative products. While certain items may be available via resellers, this does not represent a viable alternative, as it introduces additional cost without addressing technical compatibility or continuity requirements. Accordingly, the proposed approach is necessary to ensure continuity of research and represents a proportionate and compliant procurement solution. This voluntary ex-ante transparency (VEAT) notice acknowledges that Trinity College Dublin proposes to put in place a contract with Becton Dickinson UK Ltd, 1030 Eskdale Road, Winnersh Triangle, Wokingham, Berkshire RG41 5TS for the provision of flow cytometry reagents, antibodies, platform-specific consumables and single-cell genomics reagents required to support ongoing research activities across the University. The requirement encompasses specialised laboratory reagents, including fluorochrome-conjugated monoclonal antibodies, staining buffers, assay kits, instrument calibration materials, and proprietary consumables associated with BD flow cytometry and BD Rhapsody single-cell genomics platforms. These products are integral to established experimental workflows across multiple research groups, including immunophenotyping, cell signalling analysis, and single-cell gene expression studies. Trinity College Dublin intends to award this contract in accordance with Article 32(2)(b)(ii) of Directive 2014/24/EU, on the basis that competition is absent for technical reasons. The required reagents are defined by specific antibody clones and fluorochrome conjugations, many of which are proprietary, and are embedded within validated experimental protocols. Substitution would necessitate extensive re-validation, introduce scientific risk, and delay research outputs. In addition, platform-specific consumables, including BD Rhapsody cartridge and cDNA kits, are required for the operation of existing instrumentation and cannot be replaced with alternative products. While certain items may be available via resellers, this does not represent a viable alternative, as it introduces additional cost without addressing technical compatibility or continuity requirements. Accordingly, the proposed approach is necessary to ensure continuity of research and represents a proportionate and compliant procurement solution.

Amtliche Quelle

Quelle: TED - Tenders Electronic Daily (Publications Office of the EU)

Prüfen Sie alle Angaben stets in der amtlichen Bekanntmachung.

Zuletzt mit TED - Tenders Electronic Daily (Publications Office of the EU) abgeglichen vor 1 Monat

Mehr von diesem Auftraggeber

Vollständiges Auftraggeberprofil

7 offene Ausschreibungen derzeit

Jüngste Vergaben

Änderungsverlauf

Jedes Mal, wenn eine offizielle Quelle diese Bekanntmachung mit geändertem Inhalt erneut veröffentlicht hat. Wir beobachten alle Quellen, die wir indexieren, auch regionale Kopien derselben Bekanntmachung.

  1. Vor dem Angebot lesen
    • Zuschlagsdatum: Zuschlag am 20. April 2026
    • Leistung und Kriterien: Die Beschreibung wurde erweitert. Vor dem Angebot erneut lesen.

Folgen Sie dieser Ausschreibung, und wir mailen Ihnen jede Änderung sofort. Konto erstellen

Ähnliche Ausschreibungen

Marktkontext

Ø offene Ausschreibung · Medizintechnik & Arzneimittel
10.142.739 €
9.882 aktuell offen in Europa
Vergabehistorie auf Aperlena
119 erfasste Bekanntmachungen · 84 vergeben
210.780.816 € vergebenes Volumen

Verpassen Sie keine Ausschreibung wie diese

2 neue Bekanntmachungen für Medizintechnik & Arzneimittel in Irland in den letzten 7 Tagen. Erhalten Sie eine E-Mail, wenn neue erscheinen. Kostenlos.

Benachrichtigung einrichten

Tastaturkürzel

Eine Liste lesen, ohne zur Maus zu greifen. In einem Eingabefeld bleiben die Kürzel stumm.

j
Nächstes Ergebnis
k
Vorheriges Ergebnis
Enter
Ergebnis öffnen
n
Nächste Seite
p
Vorherige Seite
c
Dieses Ergebnis vergleichen
s
Dieses Ergebnis auf die Merkliste setzen
/
Zum Suchfeld springen
?
Diese Kürzel anzeigen
Esc
Schließen